Could this be the end of the road for serelaxin?
AZ hopes data will boost sales of its Farxiga.
Repatha cuts cardio events, but not mortality.
PRAC to review Uptravi after five deaths in France.
Xarelto aces outcomes trial and could have edge over Boehringer and BMS rivals.
Sales of Praluent can continue during patent case appeal.
Health systems should fund more treatments for chronic diseases, says EFPIA